| 59.44 -1.18 (-1.95%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 75.63 | 1-year : | 80.27 |
| Resists | First : | 64.75 | Second : | 68.73 |
| Pivot price | 63.57 |
|||
| Supports | First : | 58.31 | Second : | 48.52 |
| MAs | MA(5) : | 60.6 |
MA(20) : | 64.24 |
| MA(100) : | 56.11  |
MA(250) : | 41.71 |
|
| MACD | MACD : | -0.8 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 15.4 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 68.73 | Low : | 22.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TVTX ] has closed above bottom band by 9.5%. Bollinger Bands are 33.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 60.97 - 61.26 | 61.26 - 61.56 |
| Low: | 58.18 - 58.55 | 58.55 - 58.92 |
| Close: | 58.75 - 59.34 | 59.34 - 59.92 |
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Thu, 24 Sep 2026
TVTX: Strong FILSPARI launch, robust pipeline progress, and patent protection through 2037 highlighted - TradingView
Wed, 23 Sep 2026
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - Yahoo Finance
Wed, 23 Sep 2026
A kidney drug could get U.S. patent protection for some uses into October 2037. - Stock Titan
Tue, 22 Sep 2026
Why Everyone Is Watching Travere Therapeutics (TVTX) Today - simplywall.st
Tue, 22 Sep 2026
Travere Therapeutics appoints new CEO Bradley Campbell - The Globe and Mail
Tue, 22 Sep 2026
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 115 (%) |
| Shares Short | 11,940 (K) |
| Shares Short P.Month | 12,020 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | -7.4 % |
| Operating Margin | 2.3 % |
| Return on Assets (ttm) | -3.8 % |
| Return on Equity (ttm) | -236.4 % |
| Qtrly Rev. Growth | 48.2 % |
| Gross Profit (p.s.) | 3.71 |
| Sales Per Share | 6.27 |
| EBITDA (p.s.) | 0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 93 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -81.43 |
| PEG Ratio | 0 |
| Price to Book value | 55.55 |
| Price to Sales | 9.47 |
| Price to Cash Flow | 60.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|